Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

For patients with metastatic HR+/HER2— breast cancer, there were various trials to have come out of ASCO 2025 that are worth keeping your eye on.

Tel Aviv University researchers say neutrophils can be late-stage breast cancer target and biomarker; Beilinson Hospital ...

Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for KISQALI® (ribociclib ...

University of Cambridge study shows how LLM GPT-4 can generate novel combinations of drugs not typically used to treat cancer ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

HER2-positive cancers are fueled by an overactive HER2 gene, which makes too much of a protein called human epidermal growth factor receptor 2 that helps cancer cells grow and spread. Patients with ...

Adding dalpiciclib to adjuvant endocrine therapy can improve outcomes in patients with HR-positive, HER2-negative early breast cancer.

Emerging research continues to spotlight the potential role of diet in cancer prevention, with olive oil—a cornerstone of the Mediterranean diet&mdas | Drug Discovery And Development ...